Next |
home / stock / onct / onct message board
Subject | By | Source | When |
---|---|---|---|
I think that $ONCT has huge potential, but | Tartiaboy | investorshub | 03/31/2023 5:25:45 PM |
znewcar1: $ONCT 24% v528K c.8778 f58,711M H.878 ML.5951 | znewcar1 | investorshangout | 03/23/2023 9:00:25 PM |
Tartia or Decaf, Time to buy more, or sell?tia | spiderman3600 | investorshub | 03/10/2023 4:33:35 PM |
https://stocktwits.com/Stockholm111/message/509113960 | spiderman3600 | investorshub | 01/30/2023 9:48:44 PM |
I am anxiously waiting for $ONCT to initiate | Tartiaboy | investorshub | 01/27/2023 5:32:44 PM |
Good news. I'll take it when I | zetatauri | investorshub | 01/23/2023 7:06:25 PM |
https://stocktwits.com/Stockholm111/message/507665767 | spiderman3600 | investorshub | 01/23/2023 6:27:36 PM |
Oncternal Therapeutics Announces the Appointment of Jill DeSimone | zetatauri | investorshub | 01/11/2023 3:32:20 PM |
SEC filing 8-k > On August 30, 2022, | crudeoil24 | investorshub | 08/31/2022 12:40:58 PM |
-- Interim Phase 1/2 results for zilovertamab | TechandBio | investorshub | 08/24/2022 12:11:31 PM |
64k on the bid. | TechandBio | investorshub | 08/22/2022 7:51:14 PM |
Oncternal therapeutics: Zilovertamab Phase 3 study Ror1 ZILO-301 | TechandBio | investorshub | 08/22/2022 12:06:20 PM |
Expected Upcoming Milestones | crudeoil24 | investorshub | 08/22/2022 3:04:15 AM |
That 15.00 PT will be broken on | crudeoil24 | investorshub | 08/19/2022 7:42:16 PM |
Analyst update for $ONCT | TechandBio | investorshub | 08/19/2022 6:15:03 PM |
Phase 3 with $ABBV that makes their blockbuster | TechandBio | investorshub | 08/18/2022 10:56:36 PM |
Positive fundamental & technical catalysts taking $ONCT share | crudeoil24 | investorshub | 08/18/2022 12:05:41 PM |
Building higher support level broke the 50 day | TechandBio | investorshub | 08/18/2022 10:06:24 AM |
Anticipated Pipeline Milestones | TechandBio | investorshub | 08/17/2022 9:59:02 PM |
Oncternal Therapeutics Provides Business Update. | TechandBio | investorshub | 08/17/2022 9:53:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets clo...
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-5...